Abstract
Objective: To investigate the distribution characteristics of peripheral blood lymphocyte subsets in patients with Pituitary Neuroendocrine Tumors (PitNETs) based on the 2022 WHO classification and analyze their relationship with clinical features.
Methods: A total of 230 patients with pathologically confirmed PitNETs were enrolled. Absolute counts and percentages of T cells, B cells, NK cells, and CD4+/CD8+ ratios were detected via flow cytometry and compared with 102 healthy controls. Subgroup analyses were performed according to cell lineage, clinical functional type, and Knosp grading.
Results: PitNET patients showed decreased absolute lymphocyte counts and NK cell proportions, while B cell, T cell proportions, and CD4+/CD8+ ratios were increased (all P < 0.05). These alterations correlated with tumor lineage, size, and invasiveness (Knosp grade).
Conclusion: PitNETs are associated with systemic immune dysfunction. Peripheral blood analysis offers a non-invasive window into the immune status of these patients, potentially guiding future immunotherapy.
Introduction
Pituitary Neuroendocrine Tumors (PitNETs) are common intracranial neoplasms. While research often focuses on the local tumor immune microenvironment (TIME), the systemic immune impact of these tumors remains poorly understood. Understanding the peripheral immune profile is vital for identifying non-invasive biomarkers and assessing patient readiness for emerging immunotherapies like immune checkpoint inhibitors.
Methods and Materials
This cross-sectional study included 230 patients with pathologically confirmed PitNETs at Peking Union Medical College Hospital (March–October 2023). A control group of 102 healthy adults provided reference values. Peripheral blood immunophenotyping was performed using flow cytometry to measure T cells (CD3+, CD4+, CD8+), B cells (CD19+), and NK cells (CD16+/CD56+). Tumors were classified according to the 2022 WHO cell lineage criteria (PIT1, TPIT, SF1) and graded for invasiveness using the Knosp scale.
Results
Systemic Immune Dysregulation Across Lineages
Compared to healthy controls, PitNET patients exhibited a significant decrease in Natural Killer (NK) cell proportions (~11.5% vs 20.0%) and absolute lymphocyte counts. Conversely, the proportions of B cells, T cells, and the CD4+/CD8+ ratio were elevated. These trends were consistent across major lineages, including PIT1, TPIT, and SF1.
Correlation with Clinical Features
Subgroup analysis revealed that immune alterations were most pronounced in non-functioning and growth hormone (GH) adenomas. Tumor size and invasiveness also played a role:
- Tumor Size: Larger volumes correlated with lower B cell proportions (r = -0.114, P < 0.05).
- Invasiveness: Higher Knosp grades were associated with increased CD4+ T cell proportions (r = 0.112, P < 0.05) and decreased B cell proportions.
Interestingly, no significant differences were found between primary and recurrent tumors, suggesting that systemic immune shifts occur early in disease progression.
Discussion
The findings suggest that PitNETs drive systemic immune dysfunction, likely through the "neuro-endocrine-immune network." The reduction in NK cells—the body's first line of defense against tumors—indicates weakened immune surveillance. The simultaneous rise in T and B cell proportions may represent a compensatory but ineffective immune response.
The correlation between immune profiles and tumor invasiveness (Knosp grade) suggests that aggressive tumors may induce persistent systemic immune activation or exhaustion. While this study is limited by its cross-sectional design and single-center data, it highlights peripheral blood analysis as a promising tool for clinical assessment and personalized treatment planning in PitNET patients.
Summary updated